Biotech
Discovery Labs DSCO expects to learn Thursday, May 1, whether U.S. drug regulators will approve its lung surfactant Surfaxin as a treatment for premature infants suffering from respiratory distress. This is the third time Discovery has brought Surfaxin to the Food and Drug Administration. Manufacturing and quality control issues have stymied the previous stabs at approval. In recent public forums and conference calls, Discovery management has sounded confident that it's solved all FDA concerns this time around. The stock, long battered due to the Surfaxin delays, has started to rebound as investors anticipate better news from the FDA this time around. From an investor angle, the ugly truth about Discovery, however, is that the commercial opportunity for Surfaxin right now is relatively small, and with well over 90 million shares outstanding, it's going to be hard for the company to generate much value from an approval. Discovery is currently trading around $2.82 a share. An approval Thursday might pop the stock to about $5, but it's not really worth much more than that until the company can meaningfully expand Surfaxin use or make progress on its drug development pipeline. Two analysts covering the company -- Jon Aschoff at Brean Murray Carret and Adam Walsh at Jefferies -- both have $5 price targets on Discovery, assuming that Surfaxin gets approved this week.
How Surfaxin Works
A surfactant is like lubrication for the lungs. Think of it as a slick goo that surrounds and coats the air sacs in the lungs, making them flexible and allowing them to absorb oxygen.The drug failed to benefit patients with lupus, according to new late-stage study data.
Data presented this weekend show telaprevir is the leader.
What to expect when ImClone presents the latest Erbitux data at ASCO in June.
Apple and AT&T were among the most searched stocks on TheStreet.com Friday. Here's what Cramer had to say about them recently.
Catch up on his thinking on the hottest topics of the past week.
Investors will have to deal with a Fed meeting and another flood of earnings and economic data.
Looking for deep value with Defiance Asset Management, polling big investors about where the market's headed, plus much more.
See who made what calls.
3 Stocks I Saw On TVDan Fitzpatrick examines three stocks viewed on Fast Money and Mad Money Today's stocks include Deere & Co., Petrobras and MBIA
TheStreet.com Ratings checks in on First Community Bancorp and First Niagara Financial Group two months after recommending the stock.
Take-Two's latest hit receives a perfect score from industry reviewers.
- Cramer's 'Mad Money' Recap: Mad Money's Rally Playbook
- The Polycarbonate Price Cut
- CalPERS Pushes for Clean House at Standard Pacific
- Investing in China: What You Need to Know
- Coming Week: 'Glimmer of Hope'
- Top Stocks With Insider Buying, Buybacks
- New Solar ETF Helps Spread Sector's Risk
- Feuerstein's Biotech-Stock Mailbag
- Need to Own Energy? Here's How to Do It
- My Company Doesn't Provide Health Insurance (Gulp!)
Sponsored by:

BEAT THE STREET GAME:



